Gemtuzumab ozogamicin for acute myeloid leukemia.
Frederick R AppelbaumIrwin D BernsteinPublished in: Blood (2017)
On 1 September 2017, the US Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33+ acute myeloid leukemia and for patients aged ≥2 years with CD33+ acute myeloid leukemia who have experienced a relapse or who have not responded to initial treatment. This signals a new chapter in the long and unusual story of GO, which was the first antibody-drug conjugate approved for human use by the FDA.
Keyphrases
- acute myeloid leukemia
- newly diagnosed
- drug administration
- acute lymphoblastic leukemia
- end stage renal disease
- allogeneic hematopoietic stem cell transplantation
- endothelial cells
- chronic kidney disease
- ejection fraction
- prognostic factors
- risk assessment
- peritoneal dialysis
- climate change
- replacement therapy
- patient reported